The Manufacturers Life Insurance Company increased its holdings in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 0.9% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 454,984 shares of the medical research company's stock after buying an additional 4,240 shares during the period. The Manufacturers Life Insurance Company owned 0.25% of IQVIA worth $107,818,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors and hedge funds have also bought and sold shares of the company. Qsemble Capital Management LP increased its holdings in IQVIA by 169.2% in the 3rd quarter. Qsemble Capital Management LP now owns 12,061 shares of the medical research company's stock worth $2,858,000 after purchasing an additional 7,580 shares in the last quarter. Associated Banc Corp raised its holdings in IQVIA by 1.2% during the 3rd quarter. Associated Banc Corp now owns 129,277 shares of the medical research company's stock worth $30,635,000 after purchasing an additional 1,592 shares during the last quarter. Private Trust Co. NA boosted its position in IQVIA by 10.7% during the third quarter. Private Trust Co. NA now owns 485 shares of the medical research company's stock valued at $115,000 after acquiring an additional 47 shares during the last quarter. Fisher Asset Management LLC lifted its stake in shares of IQVIA by 4.8% in the 3rd quarter. Fisher Asset Management LLC now owns 7,398 shares of the medical research company's stock valued at $1,753,000 after purchasing an additional 341 shares during the period. Finally, Daiwa Securities Group Inc. boosted its position in shares of IQVIA by 5.1% during the 3rd quarter. Daiwa Securities Group Inc. now owns 37,651 shares of the medical research company's stock valued at $8,922,000 after purchasing an additional 1,828 shares in the last quarter. Institutional investors own 89.62% of the company's stock.
Wall Street Analyst Weigh In
A number of equities analysts have issued reports on IQV shares. TD Cowen cut their price target on IQVIA from $270.00 to $255.00 and set a "buy" rating on the stock in a report on Friday, November 1st. Deutsche Bank Aktiengesellschaft dropped their price objective on shares of IQVIA from $270.00 to $265.00 and set a "buy" rating on the stock in a report on Friday, November 1st. Morgan Stanley reduced their price target on shares of IQVIA from $280.00 to $265.00 and set an "overweight" rating for the company in a research report on Monday, November 4th. The Goldman Sachs Group cut their price target on IQVIA from $280.00 to $250.00 and set a "buy" rating for the company in a research note on Friday, November 1st. Finally, Robert W. Baird cut their price objective on shares of IQVIA from $256.00 to $223.00 and set a "neutral" rating on the stock in a report on Friday, November 1st. Four equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, IQVIA presently has a consensus rating of "Moderate Buy" and an average price target of $256.50.
Check Out Our Latest Stock Analysis on IQVIA
IQVIA Price Performance
IQVIA stock traded up $0.21 during midday trading on Wednesday, reaching $201.44. 822,728 shares of the stock were exchanged, compared to its average volume of 1,177,509. The company's fifty day moving average is $220.36 and its 200-day moving average is $226.57. The company has a debt-to-equity ratio of 1.76, a quick ratio of 0.81 and a current ratio of 0.81. IQVIA Holdings Inc. has a 52 week low of $187.62 and a 52 week high of $261.73. The firm has a market cap of $36.56 billion, a PE ratio of 26.44, a PEG ratio of 2.10 and a beta of 1.51.
IQVIA Company Profile
(
Free Report)
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
See Also
Before you consider IQVIA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.
While IQVIA currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
